ArticleCureus2025
Surgical Outcomes and Complications of Patients With Acromegaly in Qatar.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcromegaly is a rare endocrine disorder. It results from excess growth hormone (GH) secretion, predominantly due to pituitary adenomas. Endoscopic trans-nasal transsphenoidal (ETT) resection remains the primary treatment modality. Adjunctive medical and radiotherapeutic interventions are required for incomplete remission. This study evaluates the surgical outcomes and complications in patients with acromegaly managed at Hamad General Hospital (HGH), Qatar.
methodsThis retrospective study includes patients diagnosed with acromegaly and managed at HGH between January 2010 and May 2025. Only patients with confirmed acromegaly and available preoperative and postoperative hormonal assessments and imaging were included. Hormonal remission rates, extent of tumor resection, and postoperative complications were the key outcomes.
resultsA total of 45 patients were included; 23 underwent surgery at HGH. The median patient age was 43 years, with a total of 39 males. ETT resection was the sole surgical modality. Postoperatively sustained biochemical remission was observed in most cases at 12-month follow-up with lowered insulin-like growth factor-1 levels (IGF-1). Lower recurrence rates (17.3% vs. 8.88%) and a higher proportion of complete tumor resection were evident in the group of patients operated at HGH. Postoperative pituitary function was preserved in 73.9% of patients with a low incidence of complications such as cerebrospinal fluid (CSF) leaks, diabetes insipidus, and infections. Histopathology revealed a predominance of densely granulated somatotroph adenomas in the HGH group, associated with improved surgical outcomes.
conclusionETT surgery remains an effective primary treatment for acromegaly. Favorable biochemical remission rates and tumor resection outcomes are observed in patients managed at HGH. The predominance of densely granulated somatotroph adenomas in this cohort may have contributed to the observed favorable surgical outcomes. Further large multicenter studies are warranted to validate these conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.